A case report of long treatment with Itraconazole in a patient with chronic Chagas disease

[1]  I. Almeida,et al.  Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. , 2018, The Lancet. Infectious diseases.

[2]  R. Tarleton,et al.  Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure , 2017, bioRxiv.

[3]  F. Supek,et al.  Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease , 2015, Antimicrobial Agents and Chemotherapy.

[4]  I. Molina,et al.  Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers , 2015, Antimicrobial Agents and Chemotherapy.

[5]  E. Chatelain,et al.  Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging , 2015, Antimicrobial Agents and Chemotherapy.

[6]  J. Urbina.  Recent Clinical Trials for the Etiological Treatment of Chronic Chagas Disease: Advances, Challenges and Perspectives , 2015, The Journal of eukaryotic microbiology.

[7]  Fernando Salvador,et al.  Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. , 2014, The New England journal of medicine.

[8]  J. Urbina,et al.  Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments , 2013, PLoS neglected tropical diseases.

[9]  G. Espinosa,et al.  Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. , 2010, The American journal of tropical medicine and hygiene.

[10]  S. Sauleda,et al.  Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. , 2007, Acta tropica.

[11]  Rodolfo Viotti,et al.  Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment , 2006, Annals of Internal Medicine.

[12]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[13]  D. Loebenberg,et al.  Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan ParasiteTrypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts , 2000, Antimicrobial Agents and Chemotherapy.

[14]  R. Santos,et al.  Reativação da infecção por Trypanosoma cruzi em paciente com síndrome de imunodeficiência adquirida , 1999 .

[15]  A. Hasslocher-Moreno,et al.  [Reactivation of Trypanosoma cruzi infection in patients with acquired immunodeficiency syndrome]. , 1999, Revista da Sociedade Brasileira de Medicina Tropical.

[16]  P. Wincker,et al.  Antiproliferative Effects and Mechanism of Action of SCH 56592 against Trypanosoma (Schizotrypanum)cruzi: In Vitro and In Vivo Studies , 1998, Antimicrobial Agents and Chemotherapy.

[17]  A. Solari,et al.  Effect of itraconazole on lytic antibodies levels in chronic Chagas disease. , 1997, Parasite.

[18]  L. Filardi,et al.  An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. , 1993, Memorias do Instituto Oswaldo Cruz.